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Tail suspension testUrsolic acid, a constituent from Rosmarinus ofﬁcinalis, is a triterpenoid compound which has been extensively
known for its anticancer and antioxidant properties. In the present study, we investigated the
antidepressant-like effect of ursolic acid isolated from this plant in two predictive tests of antidepressant
property, the tail suspension test (TST) and the forced swimming test (FST) in mice. Furthermore, the in-
volvement of dopaminergic system in its antidepressant-like effect was investigated in the TST. Ursolic
acid reduced the immobility time in the TST (0.01 and 0.1 mg/kg, p.o.) and in the FST (10 mg/kg, p.o.), similar
to ﬂuoxetine (10 mg/kg, p.o.), imipramine (1 mg/kg, p.o.) and bupropion (10 mg/kg, p.o.). The effect of
ursolic acid (0.1 mg/kg, p.o.) in the TST was prevented by the pretreatment of mice with SCH23390
(0.05 mg/kg, s.c., a dopamine D1 receptor antagonist) and sulpiride (50 mg/kg, i.p., a dopamine D2 receptor
antagonist). The administration of a sub-effective dose of ursolic acid (0.001 mg/kg, p.o.) in combination
with sub-effective doses of SKF38393 (0.1 mg/kg, s.c., a dopamine D1 receptor agonist), apomorphine
(0.5 μg/kg, i.p., a preferential dopamine D2 receptor agonist) or bupropion (1 mg/kg, i.p., a dual dopamine/
noradrenaline reuptake inhibitor) reduced the immobility time in the TST as compared with either drug
alone. Ursolic acid and dopaminergic agents alone or in combination did not cause signiﬁcant alterations in
the locomotor and exploratory activities. These results indicate that the antidepressant-like effect of ursolic
acid in the TST is likely mediated by an interaction with the dopaminergic system, through the activation
of dopamine D1 and D2 receptors.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Depression is projected to become the second biggest contributor
to the global burden of disease and disability by the year 2020
(Pitchot et al., 2010). It is a heterogeneous disorder often manifested
with symptoms at the psychological, behavioral and physiological
levels. Noteworthy, there are high rates of comorbidity of psychiatric
and neurodegenerative disorders, type 2 diabetes mellitus, cancer,
cardiovascular disease and depression (Evans et al., 2005; Krishnan
and Nestler, 2008).
The treatment of depression with conventional antidepressants
(i.e., monoamine oxidase inhibitors, tricyclics, selective serotonin re-
uptake inhibitors and selective noradrenaline reuptake inhibitors)dimethylsulfoxide; FST, forced
xy-3-methyl-1-phenyl-2,3,4,5-
93, (1-phenyl-7,8-dihydroxy-
ST, tail suspension test.
: +55 48 3721 9672.
gmail.com (A.L.S. Rodrigues).
vier OA license.has several drawbacks. The heterogeneity of clinical response to an-
tidepressant and susceptibility to adverse effects are major clinical
problems and support the research for new therapeutic agents to
treat depression (Brunello et al., 2002; MacGillivray et al., 2003;
Wong and Licinio, 2001). Herbal therapies may be effective alterna-
tives in the treatment of depression, as include the case of St John's
wort (Akhondzadeh and Maleki, 2006; Bilia et al., 2002; Whiskey et
al., 2001) and the search for novel pharmacotherapy from medicinal
plants and compounds isolated from plant extracts for this psychiatric
disorder has progressed signiﬁcantly (Zhang, 2004).
Aiming at searching new antidepressant agents, our group has
studied the antidepressant potential of some plant extracts (Freitas
et al., 2010; Machado et al., 2007, 2009; Rodrigues et al., 2002) and
bioactive compounds (Capra et al., 2010; Machado et al., 2008). We
have recently demonstrated that the extract of Rosmarinus ofﬁcinalis
produces an antidepressant-like effect in themouse tail suspension test
(TST) and in the forced swimming test (FST), by a mechanism depen-
dent on the interaction with the monoaminergic systems (Machado et
al., 2009). One of themain constituents present in R. ofﬁcinalis is ursolic
acid (3β-hydroxy-urs-12-en-28-oic acid), a pentacyclic triterpenoid
205D.G. Machado et al. / Pharmacology, Biochemistry and Behavior 103 (2012) 204–211compound, that has a broad range of biological effects, such as antioxi-
dant (Tsai and Yin, 2008), anti-inﬂammatory (Baricevic et al., 2001;
Benincá et al., 2011), anti-tumoral (Yan-xia et al., 2010), anti-diabetic
(Jang et al., 2009) and neuroprotective (Lu et al., 2007; Shih et al.,
2004). Noteworthy, ursolic acid was shown to be able to protect PC12
cells against the dopaminergic neurotoxin MPP+ (Tsai and Yin, 2008).
Several studies have indicated that the dopaminergic system plays a
signiﬁcant role in the pathophysiology of depression and on the mech-
anisms of action of some current prescribed antidepressant agents,
mainly bupropion (D'Aquila et al., 2000; Dunlop and Nemeroff, 2007;
Papakostas, 2006). The investigation of novel antidepressant agents
that act on this system is justiﬁed to improve outcomes for patients
with treatment-resistant and non remitting depression (Dunlop and
Nemeroff, 2007). Therefore, this study aims, ﬁrstly, to examine the
antidepressant-like action of ursolic acid isolated from R. ofﬁcinalis in
the mouse TST and FST, and secondly, to investigate by the use of phar-
macological procedures the possible participation of the dopaminergic
system in its antidepressant-like action.
2. Methods
2.1. Isolation of ursolic acid from R ofﬁcinalis
Stems and leaves of R. ofﬁcinalis (Labiatae) were collected in Santo
Amaro da Imperatriz, Santa Catarina, and identiﬁed by Dr. Daniel
Falkenberg, from the Department of Botany, Federal University of
Santa Catarina. A voucher specimen (Excicata number 34918) was
deposited in the Herbarium of the Department of Botany, Federal Uni-
versity of Santa Catarina, Santa Catarina, Brazil. The procedure to ob-
tain the crude extract from R. ofﬁcinalis was described previously
(Machado et al., 2009). The crude extract was subjected to passage
on a short silica gel 60 (Vetec ‐63-230 mesh) column with hexane,
ethyl acetate and ethanol in order of polarity, to give three fractions:
the hexane (HEX), ethyl acetate (AcOEt) and ethanolic (EtOH). Part of
the AcOEt fraction (8.83 g) was submitted to the silica gel column
eluted with hexane-ethyl acetate gradient in increasing polarity, to
give 33 fractions. Fractions 20–33 eluted with hexane–acetone solu-
tion (8:2 v/v) were met and puriﬁed by ﬂash chromatography (silica
gel 60 column; Vetec‐230–400 mesh) with isocratic elution (Hexane:
Acetone 4:1 v/v) to give ursolic acid (87 mg). Ursolic acid was identi-
ﬁed by analysis of IR and NMR data and comparison with literature
(Mahato and Kundu, 1994).
2.2. Animals
Male Swiss mice (40–50 g, 60–70 days old) were maintained at
constant room temperature (21±1 °C) with free access to water and
food, under a 12:12 h light:dark cycle (lights on at 07:00 h). Mice
were allowed to acclimatize to the holding room for 24 h before the be-
havioral procedure. The animals were randomly distributed into speci-
ﬁed experimental groups. All experiments were carried out between
11:00 and 17:00 h,with each animal used only once (N=7–10 animals
per group). All procedures were performed in accordance with the Na-
tional Institute of Health Guide for the Care and Use of Laboratory Ani-
mals and approved by the Ethics Committee of the Institution. All efforts
were made to minimize animals suffering and to reduce the number of
animals used in the experiments.
2.3. Drugs and treatment
The following drugs were used: (R)-(+)-7-chloro-8-hydroxy-
3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
(SCH23390), sulpiride, apomorphine, 1-phenyl-7,8-dihydroxy-2,3,4,5-
tetrahydro-1H-3-benzazepine hydrochloride (SKF38393), ﬂuoxetine,
imipramine and bupropion, all from Sigma Chemical Company, St. Louis,
MO, U.S.A.All drugs were administered by intraperitoneal (i.p.) route, except
SCH23390 and SKF38393 that were administered by subcutaneous
(s.c.) route. All drugs were administered in a constant volume of
10 ml/kg body weight. Drugs were dissolved in saline, except
bupropion thatwere diluted in distilledwater and sulpiride thatwas di-
luted in saline with 5% dimethylsulfoxide (DMSO). Control animals re-
ceived appropriate vehicle.
Ursolic acid (0.001–10 mg/kg) was dissolved in distilled water
with 10% Tween 80 and administered acutely by oral route (p.o.).
The solution of ursolic acid was freshly done from the lyophilized
power immediately before its administration by gavage. A control
group received distilled water with 10% Tween 80 as vehicle.
2.4. Experimental design
In order to investigate the antidepressant-like effect produced by an
oral administration of ursolic acid, it was administered at the dose range
0.001–10 mg/kg (p.o.), 60 min before the TST, FST or open-ﬁeld test.
The clinically used antidepressants ﬂuoxetine (10 mg/kg, p.o.), imipra-
mine (1 mg/kg, p.o.) and bupropion (10 mg/kg, p.o.) were also admin-
istered to independent group of mice 60 min before the TST. Moreover,
bupropion (10 mg/kg, p.o.) was also administered 60 min before the
FST.
In order to investigate the involvement of the dopaminergic
system in the antidepressant-like action of ursolic acid in the TST,
the following experimental protocols were performed:
Firstly, mice were pretreated with vehicle (control group), SCH23390
(0.05 mg/kg, s.c., a dopamine D1 receptor antagonist) or sulpiride
(50 mg/kg, i.p., a dopamine D2 receptor antagonist) (Capra et al., 2010;
Machado et al., 2007) and 30 min later they received vehicle or ursolic
acid (0.1 mg/kg, p.o.). A further 60 min was allowed to elapse before
the animalswere tested in the TST or open-ﬁeld test. In order tominimize
the number ofmice used in the experiments this protocol was carried out
in the same day (same vehicle+vehicle and vehicle+ursolic acid
groups).
In a second experimental approach, we studied the possible
synergistic antidepressant-like effect elicited by the administration
of a sub-effective dose of ursolic acid (0.001 mg/kg, p.o.) with
sub-effective doses of SKF38393 (0.1 mg/kg, s.c., a dopamine D1 re-
ceptor agonist) or apomorphine (0.5 μg/kg, i.p., a preferential dopa-
mine D2 receptor agonist) (Binfaré et al., 2010; Cunha et al., in press).
Ursolic acid or vehicle were administered 30 min before the admin-
istration of the dopamine receptor agonists. In another set of
experiments, a sub-effective dose of ursolic acid (0.001 mg/kg,
p.o.) was administered immediately before the administration of
a sub-effective dose of bupropion (1 mg/kg, p.o., a dopamine/
noradrenaline reuptake inhibitor) (Cooper et al., 1994; Mortensen
and Amara, 2006; Richelson, 2003). A further 60 min was allowed
to elapse before the animals were tested in the TST or open-ﬁeld
test. In order to minimize the number of mice used in the experiments
this protocol was carried out in the same day (same vehicle+vehicle
and vehicle+ursolic acid groups).
All the experimental protocols and drug doses utilized in the pres-
ent study were based on previous studies from our group and litera-
ture (Binfaré et al., 2009, 2010; Capra et al., 2010; Cooper et al., 1994;
Cunha et al., 2008, in press; Machado et al., 2007, 2009; Mortensen
and Amara, 2006; Richelson, 2003; Rodrigues et al., 2002). These
protocols are largely standardized in our laboratory as shown in the
study of the mechanism of action of various compounds with antide-
pressant action.
2.5. Behavioral tests
2.5.1. Tail suspension test (TST)
The TST has become one of the most widely used tests for assessing
antidepressant-like activity in mice. It is based on the fact that animals
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their tail, will develop an immobile posture. The total duration of immo-
bility induced by tail suspension was measured according to the meth-
od described by Steru et al. (1985). Brieﬂy, mice both acoustically and
visually isolated were suspended 50 cm above the ﬂoor by adhesive
tape placed approximately 1 cm from the tip of the tail. Immobility
timewas recorded during a 6 min period. Micewere considered immo-
bile only when they hung passively and completely motionless. Antide-
pressant treatments reduce the time of immobility and increase active
escape behaviors displayed during inescapable situation in the TST
(Cryan et al., 2005; Machado et al., 2007, 2009). The immobility time
was recorded by an observer blind to the drug treatment.
2.5.2. Forced swimming test (FST)
The FST was carried out in mice individually forced to swim in an
open cylindrical container (diameter 10 cm, height 25 cm), containing
19 cm of water at 25±1 °C; the total duration of immobility during
the 6-min test was scored as described previously (Kaster et al., 2005;
Machado et al., 2007, 2009). Each mouse was judged to be immobile
when it ceased struggling and remained ﬂoating motion-less in the
water, making only those movements necessary to keep its head
above water. A decrease in the duration of immobility is indicative of
an antidepressant-like effect (Porsolt et al., 1977).
2.5.3. Open-ﬁeld test
To assess the possible effects of ursolic acid and the other drugs used
in the present study on locomotor and exploratory activities, an inde-
pendent group of mice was evaluated in the open-ﬁeld paradigm as
previously described (Machado et al., 2007; Rodrigues et al., 1996).
Mice were individually placed in a wooden box (40×60×50 cm)
with the ﬂoor divided into 12 equal rectangles. The number of crossings
deﬁned as the rectangles crossed by the animal with its four paws and
the number of rearings deﬁned as the animal standing upright on its
hind legs were registered during a period of 6 min. The number of
crossings was considered as indicative of locomotor activity and num-
ber of rearings was an indicative of exploratory behavior (Felipe et al.,
2007; Rodrigues et al., 1996). Crossings and rearings were recorded by
an observer blind to the drug treatment. The ﬂoor of the open-ﬁeld ap-
paratus was cleaned with 10% ethanol between tests to remove any ol-
factory cues.
2.6. Statistical analysis
Comparisons between experimental and control groups were
performed by analysis of variance (ANOVA) followed by Tukey HSD
test when appropriate. A value of Pb0.05 was considered to be
signiﬁcant.
3. Results
3.1. Effects of acute treatment with ursolic acid on the immobility time in
the TST and FST and on the locomotor and exploratory activities in the
open-ﬁeld test
The effects of the oral administration of ursolic acid on the immobil-
ity time in the TST and FST are shown in Fig. 1. Ursolic acid given by oral
route decreased the immobility time in the TST (at the dose of 0.01 and
0.1 mg/kg, Fig. 1A) and FST (10 mg/kg, Fig. 1E) as compared to the con-
trol group. The percent of reduction in the immobility time was 19.4%,
27.1% in the TST and 13.5% in the FST, respectively. Fig. 1E also shows
that the antidepressant buproprion (10 mg/kg, p.o., positive control)
reduced the immobility time in the FST (34.7% of reduction). The
one-way ANOVA revealed a signiﬁcant effect of ursolic acid in TST
[F(5,41)=4.32, Pb0.01] and in the FST [F(4,31)=24.76, Pb0.01]. The
effects of the oral administration of ursolic acid (dose range 0.001–
10 mg/kg) in the open-ﬁeld test are shown in Table 1. The acuteadministration of this compound did not cause any signiﬁcant change
in the locomotor activity of mice as compared to control group
[F(5,43)=2.11, P=0.08]. Moreover, as shown in Table 1, ursolic acid
did not signiﬁcantly alter the number of rearings in the open-ﬁeld test
as compared to the control group [F(5,43)=1.10, P=0.37].
Additionally, Fig. 1 shows that ﬂuoxetine (a selective serotonin re-
uptake inhibitor— SSRI, Fig. 1B), imipramine (a tricyclic antidepressant,
Fig. 1C) and bupropion (a dual dopamine/noradrenaline reuptake in-
hibitor, Fig. 1D), administered at the doses of 10, 1 and 10 mg/kg, p.o.,
respectively, were effective in the TST (reduction of 28.5%, 28.8% and
21.6% in the immobility time, respectively). The one-way ANOVA re-
vealed a signiﬁcant effect of treatment of ﬂuoxetine [F(1,14)=22.82;
Pb0.01], imipramine [F(1,15)=56.57; Pb0.01] and bupropion treat-
ment [F(1,16)=9.14; Pb0.01].
3.2. Investigation of the dopaminergic mechanisms underlying the
antidepressant-like effect of ursolic acid in the TST
The results shown in Fig. 2A indicate that the pretreatment of mice
with SCH23390 (0.05 mg/kg, s.c.) prevented the antidepressant-like ef-
fect elicited by ursolic acid (0.1 mg/kg, p.o.) in the TST. This effect was
observed when compared the SCH23390+ursolic acid group with the
antidepressant-like effect of ursolic acid showed in the vehicle+ursolic
acid group. A two-way ANOVA revealed signiﬁcant differences for
SCH23390 pretreatment [F(1, 30)=30.42, Pb0.01], ursolic acid treat-
ment [F(1, 30)=14.79, Pb0.01] and SCH23390 pretreatment×ursolic
acid treatment interaction [F(1, 30)=18.08, Pb0.01]. Moreover,
Fig. 2B illustrates that the pretreatment with sulpiride (50 mg/kg, i.p.)
also prevented the antidepressant-like effect of ursolic acid (0.1 mg/
kg, p.o.) in the TST. This effect was observed when compared the
sulpiride+ursolic acid group with the antidepressant-like effect of
ursolic acid showed in the vehicle+ursolic acid group. A two-way
ANOVA revealed signiﬁcant differences for sulpiride pretreatment
[F(1, 29)=41.19, Pb0.01], ursolic acid treatment [F(1, 29)=11.42,
Pb0.01] and sulpiride pretreatment×ursolic acid treatment interaction
[F(1, 29)=30.57, Pb0.01].
Table 2 shows that ursolic acid (0.1 mg/kg, p.o.) administered
alone or in combination with SCH23390 (0.05 mg/kg, s.c.) did not sig-
niﬁcantly cause changes in the locomotor activity of mice in the
open-ﬁeld test. The two-way ANOVA showed no signiﬁcant effects of
SCH23390 pretreatment [F(1,30)=0.71, P=0.40], ursolic acid treat-
ment [F(1, 30)=1.35, P=0.25] and SCH23390 pretreatment×ursolic
acid interaction [F(1, 30)=0.96, P=0.33]. Similarly, administration of
ursolic acid alone or in combination with SCH23390 did not cause any
change in the rearing responses. The two-way ANOVA showed no
signiﬁcant effects of SCH23390 pretreatment [F(1,30)=0.01, P=0.92],
ursolic acid treatment [F(1, 30)=1.94, P=0.17] and SCH23390
pretreatment×ursolic acid interaction [F(1, 30)=1.32, P=0.26].
Sulpiride (50 mg/kg, i.p.) alone or in combination with ursolic
acid (0.1 mg/kg, p.o.) did not cause any signiﬁcant alteration in the
number of crossings and rearings in the open-ﬁeld. Regarding cross-
ing responses, two-way ANOVA showed no signiﬁcant effects of
sulpiride pretreatment [F(1, 29)=0.03, P=0.85], ursolic acid treat-
ment [F(1, 29)=0.54, P=0.46] and sulpiride pretreatment×ursolic
acid interaction [F(1, 29)=0.32, P=0.57]. Concerning rearings re-
sponses, two-way ANOVA showed no signiﬁcant effects of sulpiride
pretreatment [F(1, 29)=0.007, P=0.93], ursolic acid treatment
[F(1, 29)=0.94, P=0.33] and sulpiride pretreatment×ursolic acid
interaction [F(1, 29)=0.54, P=0.46].
Additionally, in order to reinforce the notion that the
antidepressant-like effect of ursolic acid in the TST is dependent on
the activation of dopamine D1 and D2 receptors, in another set of
experiments we investigated the effect of the administration of a
sub-effective dose of ursolic acid (0.001 mg/kg, p.o.) in combination
with sub-effective doses of the dopamine D1 receptor agonist
SKF38393, the preferential dopamine D2 receptor agonist apomorphine
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Fig. 1. Effect of the acute treatment of mice with ursolic acid (0.001–10 mg/kg, p.o., panel A), ﬂuoxetine (10 mg/kg, p.o., panel B), imipramine (1 mg/kg, p.o., panel C) and
bupropion (10 mg/kg, p.o., panel D), on the immobility time in the TST. Panel E shows the effect of ursolic acid (0.1–10 mg/kg, p.o) and bupropion (10 mg/kg, p.o.) in the FST.
Each column represents the mean+S.E.M. of 7–10 animals. *Pb0.05, **Pb0.01 compared with the vehicle-treated control (C).
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shown in Fig. 3A, a sub-effective dose of ursolic acid (0.001 mg/kg,
p.o.) produced a synergistic antidepressant-like effect with SKF38393
(0.1 mg/kg, s.c.), since the combined treatment produced a signiﬁcant
reduction (39.6%) in the immobility time as compared to the control
group. The two-way ANOVA revealed signiﬁcant differences of ursolic
acid pretreatment [F(1, 29)=27.87, Pb0.01], SKF38393 treatment
[F(1, 29)=4.56, Pb0.05] and ursolic acid pretreatment×SKF38393
treatment interaction [F(1, 29)=10.60, Pb0.01]. The results showed
in Fig. 3B indicate that the combined administration of apomorphine
(0.5 μg/kg, i.p.) with ursolic acid (0.001 mg/kg, p.o.) produced a signif-
icant reduction (30.4%) in the immobility time as compared to the con-
trol group. The two-way ANOVA revealed signiﬁcant differences of
ursolic acid pretreatment [F(1, 29)=20.83, Pb0.01] and ursolic acid
pretreatment×apomorphine treatment interaction [F(1, 29)=6.94,
Pb0.01], but not of apomorphine treatment [F(1, 29)=2.48, P=0.12].
Fig. 3C shows that a sub-effective dose of ursolic acid (0.001 mg/kg,
p.o.) combined with a sub-effective dose of bupropion (1 mg/kg, p.o.)
also caused an antidepressant-like effect (39.4% reduction in theimmobility time) in the TST. The two-way ANOVA revealed signiﬁcant
differences of ursolic acid treatment [F(1, 30)=16.85, Pb0.01],
bupropion treatment [F(1, 30)=10.55, Pb0.01] and ursolic treatment
acid×bupropion treatment interaction [F(1, 30)=4.41, Pb0.05].
Table 3 shows that ursolic acid (0.001 mg/kg, p.o.) alone or in
combination with SKF38393 (0.1 mg/kg, s.c.) did not cause any
change in the locomotor activity of mice, as revealed by two-way
ANOVA: ursolic acid pretreatment [F(1, 28)=2.69, P=0.11],
SKF38393 treatment [F(1, 28)=0.02, P=0.88] and ursolic acid×
SKF38393 interaction [F(1, 28)=1.103, P=0.75]. Also, the number
of the rearings of mice treated with ursolic acid and/or SKF38393
was not signiﬁcantly different from the control group. The two-way
ANOVA showed no signiﬁcant differences for ursolic acid treatment
[F(1, 28)=2.00, P=0.16], SKF38393 treatment [F(1, 28)=0.20,
P=0.65] and ursolic acid×SKF38393 interaction [F(1, 28)=0.13,
P=0.72] on rearing responses.
Similarly, Table 3 shows that ursolic acid (0.001 mg/kg, p.o.) alone
or in combination with apomorphine (0.5 μg/kg, i.p.) caused no sig-
niﬁcant effects on the number of crossings and rearings in the
Table 1
Effect of the acute treatment of mice with ursolic acid (0.001–10 mg/kg, p.o.) in the
number of crossings and rearings in the open-ﬁeld test.
Group: Dose (mg/kg, p.o.) N Number of crossings Number of rearings
Vehicle – 9 58.88±8.99 19.88±4.27
Ursolic acid 0.001 8 27.75±11.95 14.00±5.31
Ursolic acid 0.01 8 32.37±10.90 13.63±5.55
Ursolic acid 0.1 8 28.75±9.29 11.63±4.52
Ursolic acid 1 8 13.75±4.75 4.00±1.49
Ursolic acid 10 8 36.38±14.52 13.00±6.88
Results are expressed as mean±S.E.M.
Table 2
Effect of the administration of ursolic acid (0.1 mg/kg, p.o.) alone or in combination
with SCH23390 (0.05 mg/kg, s.c.) or sulpiride (50 mg/kg, i.p.) in the number of the
crossings and rearings in the open-ﬁeld test.
Experimental group N Number of crossings Number of rearings
Vehicle×vehicle 9 26.77±14.26 10.11±5.29
SCH23390×vehicle 8 28.12±8.30 15.12±3.69
Vehicle×ursolic acid 8 25.00±9.19 9.12±4.25
SCH23390×ursolic acid 9 7.22±3.62 4.88±2.12
Sulpiride×vehicle 7 30.86±9.21 12.86±4.12
Sulpiride×ursolic acid 9 16.88±7.28 5.66±2.44
Results are expressed as mean±S.E.M.
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treatment [F(1, 28)=0.45, P=0.50], apomorphine treatment [F(1,
28)=0.70, P=0.40] and ursolic acid×apomorphine interaction
[F(1, 28)=1.07, P=0.30]; Rearings: ursolic acid pretreatment [F(1,
28)=0.00, P=0.96], apomorphine treatment [F(1, 28)=0.16, P=
0.28] and ursolic acid×apomorphine interaction [F(1, 28)=1.06,
P=0.31].
Table 3 also shows that the pretreatment of ursolic acid (0.001 mg/
kg, p.o.) and bupropion (1 mg/kg, p.o.) alone or in combination did not
cause any change in the crossing and rearing responses in the
open-ﬁeld test, as revealed by two-way ANOVA. Crossings: ursolic
acid treatment [F(1, 28)=0.38, P=0.54], bupropion treatment [F(1,
28)=0.84, P=0.36] and ursolic acid×bupropion interaction [F(1,
28)=1.16, P=0.29]; Rearings: ursolic acid treatment [F(1, 28)=0.29,
P=0.59], bupropion treatment [F(1, 28)=0.73, P=0.39] and ursolic
acid×bupropion interaction [F(1, 28)=0.01, P=0.93].
4. Discussion
This study shows, to our knowledge for the ﬁrst time, that the acute
administration of ursolic acid by p.o. route is effective to produce a sig-
niﬁcant antidepressant-like response in both TST and FST inmice. Note-
worthy, ursolic acid caused a reduction in the immobility time at a0
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Fig. 2. Effect of pretreatment of mice with SCH23390 (0.05 mg/kg, s.c., a dopamine D1
receptor antagonist; panel A) or sulpiride (50 mg/kg, i.p., a dopamine D2 receptor an-
tagonist; panel B) on the ursolic acid (0.1 mg/kg, p.o)-induced reduction in immobility
time in the TST. Each column represents the mean+S.E.M. of 8–9 animals. **Pb0.01
compared with the vehicle-treated control. #Pb0.01 as compared with ursolic acid
group pretreated with vehicle.lower dose in the TST (0.01 and 0.1 mg/kg, p.o.) as compared to the
FST (10 mg/kg, p.o.). Interestingly, the U-shaped dose–response curve
of ursolic acid in the TST is similar to the dose–response curve of
other compounds isolated from plants, such as berberine, rutin,
nobiletin, isoliquiritin in the FST and in the TST (Machado et al., 2008;
Peng et al., 2007; Yi et al., 2011; Wang et al., 2008) and ascorbic acid
in the TST (Binfaré et al., 2009).Moreover, the antidepressant-like effect
of ursolic acid was similar to the effect produced by the classical antide-
pressants ﬂuoxetine, imipramine and bupropion in the TST and
bupropion in the FST.
The TST and FST are reported to be predictive tests of antidepressant
action sensitive to the acute administration of antidepressant drugsVehicle SKF38393
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Fig. 3. Effect of a sub-effective dose of ursolic acid (0.001 mg/kg, p.o) in combination with
SKF38393 (0.1 mg/kg, s.c., a dopamine D1 receptor agonist; panel A), apomorphine
(0.5 μg/kg, i.p., a dopamine D2 receptor agonist; panel B) or bupropion (1 mg/kg, p.o, a
dual dopamine/noradrenaline reuptake inhibitor, panel C) in the TST. Each column
represents the mean+S.E.M. of 7–9 animals. *Pb0.05, **Pb0.01 compared with the
vehicle-treated control.
Table 3
Effect of the administration of ursolic acid (0.001 mg/kg, p.o.) alone or in combination
with SKF38393 (0.1 mg/kg, s.c.), apomorphine (0.5 μg/kg, i.p.) or bupropion (1 mg/kg,
p.o.) in the number of the crossings and rearings in the open-ﬁeld test.
Experimental group: N Number of crossings Number of rearings
Vehicle×vehicle 9 50.11±12.43 19.44±5.07
Vehicle×SKF38393 7 44.85±8.97 23.86±4.81
Vehicle×ursolic acid 7 28.00±13.79 13.71±6.13
Ursolic acid×SKF38393 9 30.00±8.70 14.22±5.38
Vehicle×apomorphine 7 25.85±10.78 8.14±2.54
Ursolic Acid×apomorphine 9 30.55±13.45 13.44±6.03
Vehicle×bupropion 7 23.71±16.41 11.71±9.86
Ursolic acid×bupropion 9 30.22±13.67 8.88±3.97
Results are expressed as mean±S.E.M.
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ioral tests induce a state of immobility in animals facing an inescapable
situation and the antidepressant-like activity of a compound is
expressed by a decrease in the immobility duration (Bourin et al.,
2005; Porsolt et al., 1977; Steru et al., 1985). It is important to note
that the TST was more sensitive to the effects of ursolic acid than the
FST, since this compound caused an antidepressant response at lower
doses than in the FST. In line with this result, Cryan et al. (2005)
reported that the TST was proposed to have a greater pharmacological
sensitivity as compared with the FST. Indeed, several evidence demon-
strate that both tests rely on different neurochemical substrates to me-
diate their behavioral effects (Bai et al., 2001; Cryan et al., 2005;
Mombereau et al., 2004).
However, it should be considered that drugs enhancing the locomo-
tor activity may give a false positive effect in this test. Thus, in order to
rule out the possibility that the reduction in the immobility time elicited
by a drug is due to an enhancement in the locomotor activity, behavior-
al tests assessing the locomotor activity of mice, such as the open-ﬁeld
test, are usually employed. In this study, we observed that the reduction
in the immobility time elicited by ursolic acid in TST is not due to a
psychostimulant action, since the doses (0.01 and 0.1 mg/kg) of this
compound, thatwere able to induce a signiﬁcant decrease in the immo-
bility time in the TST did not increase the locomotor activity in the
open-ﬁeld. Indeed, a tendency to decrease the number of crossings
and rearings in this test was observed, which may underestimate the
antidepressant-like effect of ursolic acid.
Ursolic acid is one of the main constituents of R. ofﬁcinalis (Benincá
et al., 2011). It is interesting to note that the extract from this plant
exerts antidepressant-like effect in the TST at the dose range of
10–100 mg/kg, p.o. (Machado et al., 2009). Therefore, the results
presented here indicate that ursolic acid has greater potency (but sim-
ilar efﬁcacy) as compared to the extract from R. ofﬁcinalis in the TST,
since it produces antidepressant-like effect at a dose 100–10,000 fold
lower than the active doses of the extract from R. ofﬁcinalis. These re-
sults indicate that ursolic acid exerts a signiﬁcant role in the
antidepressant-like effect of the extract of this plant in the TST.
A protective role for ursolic acid against the cell death induced by
the dopaminergic neurotoxin MPP+ in PC12 cells (Tsai and Yin,
2008) through anti-oxidative and anti-inﬂammatory mechanisms
was recently reported. Moreover, a recent study reported that ursolic
acid was able to protect haloperidol-induced catalepsy in mice
(Pemminati et al., 2011). These results suggest that this compound
might modulate the dopaminergic system. Of note, this system has
been implicated in pathophysiology of depression and in the mecha-
nism of action of some antidepressant agents (Dailly et al., 2004;
Dunlop and Nemeroff, 2007; Papakostas, 2006; Yamada et al., 2004).
Several clinical studies, including postmortem investigations, have
shown that depression may be related to reduced dopamine levels
and its metabolite homovanillic acid in the brain in depressed and/or
suicidal patients compared to normal individuals, indicating a dimin-
ished dopamine turnover (Dunlop and Nemeroff, 2007; Ebmeier et al.,2006; Papakostas, 2006). Since dopamine is the main neurotransmitter
involved in the mesocorticolimbic reward pathway, it has been pro-
posed that an increase in dopaminergic neurotransmissionmight coun-
teract the anhedonia, which is a core symptom of depression (D'Aquila
et al., 2000). Moreover, some substances thatmodulate the dopaminer-
gic system, such as bupropion, are clinically used as antidepressants
(Dhillon et al., 2008).
Animal models predictive of antidepressant action, such as the TST
show considerable responsiveness to manipulations of dopaminergic
neurotransmission (Dunlop and Nemeroff, 2007). Previous studies of
our group literature data have shown that conventional and putative
antidepressant agents (Binfaré et al., 2009, 2010; Cunha et al., 2008;
Hirano et al., 2007) as well as plant extracts and their bioactive com-
pounds whose mechanisms of action are mediated, at least in part, by
the modulation of the dopaminergic system produce positive results
in the TST (Capra et al., 2010; Freitas et al., 2010; Machado et al.,
2007, 2009; Yi et al., 2011).
The results presented here clearly indicate that the dopaminergic
system is implicated in the antidepressant-like action of ursolic acid in
the TST. This conclusion derives from some set of evidence. First, the re-
versal of the antidepressant-like effect of ursolic acid by SCH23390 or
sulpiride, selective dopamine D1 and D2 receptor antagonists, respec-
tively, is an indicative that the effect of ursolic acid in the TST is depen-
dent on the activation of these receptors. This result is somewhat in
agreement with previous studies that show that SCH23390 and
sulpiride are able to prevent the antidepressant-like effect of bupropion
in the forced swimming test (Yamada et al., 2004) and several putative
antidepressant agents in the TST (Binfaré et al., 2010; Capra et al., 2010;
Hirano et al., 2007; Machado et al., 2009; Yi et al., 2011). The second ev-
idence is given by the ﬁnding that the administration of a sub-effective
dose of ursolic acid with SKF38393 (dopamine D1 receptor agonist) or
apomorphine (a preferential dopamine D2 receptor agonist) produced
a reduction in the immobility time, as compared with the administra-
tion of either drug alone, suggesting a synergistic effect of ursolic acid
with these agonists in the TST. Moreover, a recent study reported that
the pre-treatment of mice with the dopamine D2 receptor antagonist
sulpiride (50 mg/kg, i.p.) prevented the antidepressant-like action of
apomorphine (50 μg/kg, i.p.) in the TST, indicating the involvement of
dopamine D2 receptors in the mechanism of action of apormorphine
(Cunha et al., in press). Consistent with this ﬁnding, a study demon-
strated that apomorphine activates preferentially dopamine D2 recep-
tors (16.0% more preference for D2 receptors than for D1 receptors)
(Millan et al., 2002). These results further reinforce the notion that the
antidepressant-like effect of ursolic acid in this test is dependent on
an activation of dopamine D1 and D2 receptors.
The antidepressant bupropion is a dual dopamine/noradrenaline re-
uptake inhibitor clinically used by its ability to inhibit the uptake of do-
pamine somewhat more selectively than it inhibits uptake of
noradrenaline or serotonin, although it has been shown that its effects
are at least partially mediated by a noradrenergic mechanism (Cooper
et al., 1994; Richelson, 2003; Sanchez and Hyttel, 1999). Previous stud-
ies showed a synergistic effect of antidepressant compounds such as
zinc, creatine and ascorbic acid with bupropion, administered at
sub-effective doses in the TST (Binfaré et al., 2010; Cunha et al., 2008,
in press). Similar to these results, our study showed the synergistic
antidepressant-like effect of ursolic acid with bupropion. Interestingly,
to our knowledge it is the ﬁrst evidence that ursolic acid is able to pro-
duce a synergistic antidepressant-effect with buproprion.
However, it is important to emphasize that the current results do
not allow us to indicate whether ursolic acid directly interact with do-
pamine D1 and D2 receptors or whether it enhance dopamine levels in
the synaptic cleft that in turn activates these receptors. Alternatively,
we can hypothesize that ursolic acid may enhance serotonergic trans-
mission that could, in turn, cause a dopaminergic activation. In line
with this hypothesis, several studies have suggested that SSRIs acting
on the serotonergic system may indirectly affect dopaminergic
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(Clark et al., 1996; Gobert et al., 1997; Rogóz and Gołembiowska,
2010), an action that may play a role in antidepressant-like effects
of these antidepressants. Additionally, the acute effects of several
SSRIs (Renard et al., 2001) in the FST were reversed by dopamine
D1 and D2 antagonists and the dopamine D1 agonist SKF38393 en-
hances the anti-immobility effects of SSRIs, including ﬂuoxetine,
citalopram, paroxetine and ﬂuvoxamine (Renard et al., 2001). More-
over, it has been reported that the treatment with SCH23390 and
sulpiride signiﬁcantly inhibited the effect of imipramine in the FST
and TST (Mancinelli et al., 1991; D'Aquila et al., 1994; Hirano et al.,
2007).
It should be emphasized that all the results presented here cannot be
attributed to a locomotor effect, since the administration of ursolic acid
alone or in combinationwith all the dopaminergic agents did not signif-
icantly affect the ambulatory or exploratory behavior of mice in the
open-ﬁeld test. Moreover, no signals of stereotypy were observed in
mice treatedwith ursolic acid separately or in associationwith pharma-
cological agents. Although not signiﬁcant, the decrease in locomotion
caused by combination of SCH23390 with ursolic acid might explain
the fact that SCH23390 reversed the decrease on immobility time
caused by ursolic acid in the TST. However, this hypothesis is not prob-
able considering that sub-effective doses of ursolic acid and the dopa-
mine D1 receptor agonist SKF38393 caused an anti-immobility effect
in the TST, without causing a psychostimulant effect in the open-ﬁeld
test, suggesting that dopamine D1 receptors are implicated in the
antidepressant-like effect of ursolic acid in the TST.
The importance of our results are highlighted by the fact that do-
pamine receptor agonists have been thought as one of the promising
candidates to improve outcomes of patients with treatment-resistant
and non remitting depression (Dunlop and Nemeroff, 2007; Rakofsky
et al., 2009). Moreover, here we show that the antidepressant-like ef-
fect elicited by ursolic acid (0.1 mg/kg, p.o) in the TST is similar to the
effect produced by bupropion administered at a dose 100 fold higher
(10 mg/kg, p.o.). Bupropion is a useful antidepressant for the treat-
ment of SSRI or selective noradrenaline reuptake inhibitor-resistant
depression (Baumann, 2007). Therefore, it remains to be established
if ursolic acid alone or in combination with bupropion is effective in
animals models of depression associated with anhedonia, a core
symptom of depression.
Although there is no report regarding the side-effects of ursolic acid
in humans, hepatoprotective and neuroprotective activities as beneﬁ-
cial properties of this compound were reported (Ikeda et al., 2008).
Moreover, considering that several antidepressants show adverse side
effects, which include sexual dysfunction, insomnia, gastrointestinal
disorders, hypotension (Berton and Nestler, 2006), the use of ursolic
acid in association with antidepressants such as bupropion could en-
hance their therapeutic response and decrease their side-effects by
allowing lower doses to be prescribed. Furthermore, ursolic acid dis-
plays a promising therapeutic advantage since it produced an
antidepressant-like effect similar to classical antidepressants but at
lower doses and was also reported to cause non-toxic effects (Liu,
1995), suggesting its therapeutic applicability that needs to be investi-
gated in future studies.
5. Conclusion
Thepresentwork demonstrates that ursolic acid is effective in produc-
ing an antidepressant-like effect in the TST and FSTwhen administered by
p.o. route. Moreover, a clear involvement of the dopaminergic system
in its antidepressant-like effect was indicated by the reversal of its
effect by the pretreatment of mice with dopamine D1 and D2 receptor
antagonists and also, by the synergistic antidepressant-like effect
afforded by the dopamine D1 and D2 receptor agonists, as well as
the antidepressant bupropion. Altogether, the results suggest that
an activation of dopamine D1 and D2 receptors is implicated in theantidepressant-like effect of ursolic acid in the TST. Overall, the re-
sults reported in the present study indicate the antidepressant po-
tential of ursolic acid in a preclinical test widely recognized as
effective to assess antidepressant activity, suggesting that it should
be further investigated as a possible agent for the treatment of
depression.Conﬂict of interest
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